- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
If you snooze, you don't lose
When you find a colleague sleeping by the reading console, don't bother the resting soul. A 20-minute snooze during the night shift can make the difference between finding and missing pathology.
When you find a colleague sleeping by the reading console, don't bother the resting soul. A 20-minute snooze during the night shift can make the difference between finding and missing pathology.
Naps are back in fashion, according to an editorial in The Lancet (2006;367:448). The missive arrives on the heels of an unpopular European law that mandates trainee docs work night shifts.
It also follows publication of a night-shift survival guide for junior doctors by Nicholas Horrocks and Roy Pounder at the Royal College of Physicians. The guide, according to the editorial, is "practical common sense informed by science."
You can't beat your circadian rhythms, so you might as well work with them. That means napping (no more than 45 minutes), working with maximum light exposure, sleeping successfully during the daytime, and devising an intelligent eating plan.
Who knows, you might even begin to dread the day shift. Sweet dreams . . .
Four Strategies to Address the Tipping Point in Radiology
January 17th 2025In order to flip the script on the impact of the radiology workforce shortage, radiology groups and practices need to make sound investments in technologies and leverage partnerships to mitigate gaps in coverage and maximize workflow efficiencies.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
